文献速递系统性红斑狼疮

缓解与低疾病活动状态保护狼疮患者免于新发损伤:GLADEL多民族拉美队列数据

Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
PubMed 文献 · Ann Rheum Dis · 2017-09-22

基于1350例系统性红斑狼疮(SLE)患者的多民族拉美队列(GLADEL),评估不同疾病活动状态对结局的影响。多因素Cox分析显示,缓解状态与新发损伤(HR 0.60)及严重新发损伤(HR 0.32)风险降低相关;低疾病活动状态(LDAS)仅与新发损伤风险降低相关(HR 0.66)。未观察到对死亡率有显著影响。

要点

  • 缓解状态(不论是否用药)与新发及严重新发损伤风险降低独立相关。
  • LDAS仅与新发损伤风险降低相关,对严重新发损伤无显著保护。
  • 疾病活动状态对死亡率无显著影响。

核心结论

  • 缓解状态与新发及严重新发损伤风险降低相关,LDAS仅与新发损伤风险降低相关。

研究设计与样本

  • 多民族、多国拉美SLE队列(GLADEL)研究,纳入1350例患者,采用时依变量Cox回归分析。

主要发现

  • 随访期间79例死亡,606例出现新发损伤,177例出现严重新发损伤。
  • 缓解(用药或非用药)与新发损伤风险降低相关(HR 0.60;95% CI 0.43-0.85)。
  • 缓解与严重新发损伤风险降低相关(HR 0.32;95% CI 0.15-0.68)。
  • LDAS与新发损伤风险降低相关(HR 0.66;95% CI 0.48-0.93)。
  • 未观察到疾病活动状态对死亡率有显著影响。

关键数值与推荐

  • 缓解非用药:SLEDAI=0,无泼尼松或免疫抑制剂。
  • 缓解用药:SLEDAI=0,泼尼松≤5 mg/天和/或维持性免疫抑制剂。
  • LDAS:SLEDAI≤4,泼尼松≤7.5 mg/天和/或维持性免疫抑制剂。
  • 非优化控制:SLEDAI>4和/或泼尼松>7.5 mg/天和/或诱导性免疫抑制剂。
  • 所有状态均允许使用抗疟药。

临床怎么用

  • 在SLE管理中,达到缓解或LDAS可能有助于减少新发损伤,尤其是缓解对严重损伤的保护更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate disease activity statuses' (DAS') impact on systemic lupus erythematosus (SLE) outcomes. MATERIALS AND METHODS: Four DAS were defined: remission off-therapy: SLE Disease Activity Index (SLEDAI)=0, no prednisone or immunosuppressive drugs (IS); remission on-therapy: SLEDAI=0, prednisone ≤5 mg/day and/or IS (maintenance); low (L) DAS: SLEDAI ≤4, prednisone ≤7.5 mg/day and/or IS (maintenance); non-optimally controlled: SLEDAI >4 and/or prednisone >7.5 mg/day and/or IS (induction). Antimalarials were allowed in all. Predefined outcomes were mortality, new damage (increase of at least one Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI) point) and severe new damage (increase of at least 3 SDI points). Univariable and multivariable Cox regression models were performed to define the impact of DAS, as time-dependent variable, on these outcomes. RESULTS: 1350 patients were included, 79 died during follow-up, 606 presented new and 177 severe new damage. In multivariable analyses, remission (on/off-therapy) was associated with a lower risk of new (HR 0.60; 95% CI 0.43 to 0.85), and of severe new damage (HR 0.32; 95% CI 0.15 to 0.68); low disease activity status (LDAS) was associated with a lower risk of new damage (HR 0.66; 95% CI 0.48 to 0.93) compared with non-optimally controlled. No significant effect on mortality was observed. CONCLUSIONS: Remission was associated with a lower risk of new and severe new damage; LDAS with a lower risk of new damage after adjusting for other damage confounders.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, et al. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Ann Rheum Dis. 2017. PMID: 28939626. doi:10.1136/annrheumdis-2017-211814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。